Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome.
about
An overview of the clinical use of antimuscarinics in the treatment of overactive bladderRefractory overactive bladder: a common problem?Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain.Clinical factors associated with dose escalation of solifenacin for the treatment of overactive bladder in real life practice.The medical treatment of overactive bladder, including current and future treatments.New agents to treat lower urinary tract and pelvic floor disordersPhase II drugs that target cholinergic receptors for the treatment of overactive bladder.Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study.Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study.Clinical value of a patient-reported goal-attainment measure: the global development of self-assessment goal achievement (SAGA) questionnaire for patients with lower urinary tract symptoms.Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation.European content validation of the Self-Assessment Goal Achievement (SAGA) questionnaire in patients with overactive bladder.Validation study of the Self-Assessment Goal Achievement (SAGA) questionnaire for lower urinary tract symptoms.Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder.Antimuscarinic agents in elderly people.Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms.
P2860
Q35042575-A7CACD7F-E8F8-49A5-BAFE-F92F83F27AD8Q36073640-6EB66923-109A-4E81-9F31-F9F3B2E09C35Q37300812-1BAE6DDD-BD4B-488C-8519-19EC1DDAD4F5Q37697655-06230ADE-C8EC-42C1-9FA4-B5C5798DD0E2Q37836943-C31EB102-9CAF-47BA-8836-D195BEF60DE2Q38187656-7157EA67-B273-4E72-B86F-95E8FF508115Q38217760-CE9D6038-FDF2-441C-B9D7-4679F4792538Q38352217-45322D8F-9F97-40A2-A37B-83A90E5BB3DEQ38441958-B08D2A97-74F4-450C-BC58-0AF72F04D6AFQ39211584-F764CCCB-0B93-4AAB-B9DB-2CB6EA8A76A0Q42629631-E217B9AB-4774-4C61-AEE2-5111899840EDQ44037004-16EC6A9A-DA89-496D-8876-A17A11E32E79Q44604387-498C30C5-C981-447F-BE0D-B7C4AED249FFQ47899127-14292E36-F6DC-4FBB-813F-40CBD5B06FBCQ47904242-B6EA7D67-BD1A-4A08-9EA4-4AF32A49A610Q51029994-85389A65-E3A1-4D78-8934-E2AD817A68DBQ51037347-D932E16D-F30D-4364-94F8-F407276B1C47Q51839285-D5DE7945-E31A-47BA-ADC8-2A248A3800BEQ53134307-4CCBA7E7-3A5D-4158-AF92-FA8CF474E2AB
P2860
Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Listening to the patient: a fl ...... n overactive bladder syndrome.
@en
Listening to the patient: a fl ...... n overactive bladder syndrome.
@nl
type
label
Listening to the patient: a fl ...... n overactive bladder syndrome.
@en
Listening to the patient: a fl ...... n overactive bladder syndrome.
@nl
prefLabel
Listening to the patient: a fl ...... n overactive bladder syndrome.
@en
Listening to the patient: a fl ...... n overactive bladder syndrome.
@nl
P1433
P1476
Listening to the patient: a fl ...... n overactive bladder syndrome.
@en
P2093
Francisco J Brenes
Matt T Rosenberg
P304
P356
10.1111/J.1464-410X.2009.08545.X
P577
2009-04-17T00:00:00Z